How Long Do People Stay on Wegovy for Weight Loss?

The two-year NICE figure and what it really means

If you've read that Wegovy is only meant to be taken for two years, you've encountered NICE's appraisal of semaglutide (TA875), which recommends use for a maximum of two years within a specialist NHS weight management service. That recommendation applies to NHS prescribing, where resources and service structures shape what's feasible. It doesn't mean Wegovy is unsafe beyond two years, or that a private prescriber is bound by that ceiling.

In practice, the two-year mark is better understood as a review point than a hard stop. If someone has lost less than 5% of their body weight after six months on the maintenance dose, the guidance suggests reconsidering whether to continue. If the medicine is working well and the patient's overall health picture supports it, the conversation looks quite different. A prescriber reviewing your case considers all of that, not just a calendar.

For context on how long people are typically on Wegovy, real-world evidence shows that those who stop often regain weight gradually, which prompts many to restart or continue longer-term under medical supervision. The biology doesn't switch off when treatment does.

What tends to keep people on treatment longer

There are a few factors that consistently influence whether someone stays on Wegovy beyond the initial months. Tolerability is one: the GI side effects that some people find difficult in the early weeks (nausea, loose stools, reflux) tend to ease as the body adjusts, and most people who get through that phase find a sustainable pattern. If you're curious about how quickly weight loss tends to happen on Wegovy, the early weeks often show the biggest shifts, which can itself be motivating enough to continue.

Ongoing weight loss matters too, obviously. But prescribers also look at whether the medicine is helping with weight-related health conditions (blood pressure, cholesterol, joint load, sleep apnoea) even when the scales slow down. A plateau doesn't automatically mean treatment has stopped working. That said, a one-minute check worth building in: weigh yourself at the same time of day, in the same clothes, once a week, and note the trend over four weeks rather than reacting to a single reading. A trend still heading down, even slowly, tells a different story than a flat line held for months.

Dose matters here too. Wegovy's titration path runs from 0.25mg up to a 2.4mg maintenance dose, and those who reach and sustain the higher doses generally see more consistent results. The newer 7.2mg dose, approved by the MHRA in early 2026, extends the ceiling further, for a fuller picture of the medicine and how it works, the Wegovy overview covers the key details.

When people decide to stop, and what that involves

Some people stop Wegovy because they've reached a weight that feels right, because side effects haven't settled, because their circumstances change, or because their prescriber advises against continuing. Pregnancy is one clear example: Wegovy is not recommended during pregnancy, while breastfeeding, or when trying to conceive, and a prescriber will discuss timing and what stopping looks like. For those planning a family, the guidance around washout periods is covered on our page about how long after Wegovy you can try to get pregnant.

The harder reality, documented in clinical trials and real-world follow-up, is that stopping usually means some weight comes back. That's not a failure of the person, it reflects how appetite-regulating hormones behave when the medicine is removed. It's one reason that NHS guidance on semaglutide frames this as a long-term clinical decision, not a short course like antibiotics. The weight management page on our treatment overview gives a broader look at what supervised treatment involves.

On the subject of cost across a longer treatment period, the Wegovy cost guide explains what private pricing includes and why the right question isn't which service charges the least.

Who reviews the decision, and how often

At nume, every repeat prescription is assessed individually by a GPhC-registered prescriber, not carried over automatically. That means duration is never set on autopilot. A prescriber reads your updated information each time, considers your progress, and decides whether continuing is clinically appropriate. The same clinical team that reviews your initial consultation reviews every repeat. You can meet them on the clinical team page.

Duration is also shaped by whether you're treating weight alone or alongside a condition like type 2 diabetes or cardiovascular disease, semaglutide has separately approved indications for both, and those clinical pictures involve their own review frameworks. For weight management specifically, the goal is to use the medicine for as long as it's working well, well-tolerated, and clinically indicated, not as long as a set schedule prescribes. If you're thinking about starting or have questions about continuing, starting a free consultation is the practical next step.